Defibrotide Injection

Generic name: Pronounced as (dee fy' broh tide)
Brand names
  • Defitelio®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 06/15/2016

Defibrotide injection is used to treat adults and children with hepatic veno-occlusive disease (VOD; blocked blood vessels inside the liver, also known as sinusoidal obstruction syndrome), who have kidney or lung problems after receiving a hematopoietic stem-cell transplant (HSCT; procedure in which certain blood cells are removed from the body and then returned to the body). Defibrotide injection is in a class of medications called antithrombotic agents. It works by preventing the formation of blood clots.

Defibrotide injection comes as a solution (liquid) to be injected intravenously (into a vein) over 2 hours by a doctor or nurse in a medical facility. It is usually injected once every 6 hours for 21 days, but may be given for up to 60 days. The length of treatment depends on how well your body responds to the medication and the side effects that you may experience.

Your doctor may need to delay or stop your treatment if you experience certain side effects. Be sure to tell your doctor how you are feeling during your treatment with defibrotide.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before receiving defibrotide injection,

  • tell your doctor and pharmacist if you are allergic to defibrotide, any other medications, or any of the ingredients in defibrotide injection. Ask your pharmacist for a list of the ingredients.

  • tell your doctor if you are taking or have received anticoagulants ('blood thinners') such as apixaban (Eliquis), dabigatran (Pradaxa), dalteparin (Fragmin), edoxaban (Savaysa), enoxaparin (Lovenox), fondaparinux (Arixtra), heparin, rivaroxaban (Xarelto), and warfarin (Coumadin, Jantoven) or if you will be receiving medications thrombolytic medications tissue plasminogen activators such as alteplase (Activase), reteplase (Retavase), or tenecteplase (TNKase). Your doctor will probably tell you not to use defibrotide injection if you are taking or using one or more of these medications.

  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor if you are bleeding anywhere on your body or if you have bleeding problems.

  • tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while receiving, call your doctor. Do not breastfeed while receiving defibrotide injection.

Unless your doctor tells you otherwise, continue your normal diet.

  • Defibrotide injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • dizziness

    • diarrhea

    • vomiting

    • nausea

    • nose bleeding

  • Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately or get emergency medical treatment:

    • rash

    • hives

    • itching

    • swelling of the face, lips, tongue or throat

    • unusual bleeding or bruising

    • blood in urine or stool

    • headache

    • confusion

    • slurred speech

    • vision changes

    • fever, cough, or other signs of infection

  • Defibrotide injection may cause other side effects. Call your doctor if you have any unusual problems while receiving this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests to check your body's response to defibrotide injection.

Ask your pharmacist any questions you have about defibrotide injection.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Anagrelide Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Defibrotide.
Calcium Carbonate Calcium Carbonate The therapeutic efficacy of Calcium carbonate can be decreased when used in combination with Defibrotide.
Cilostazol Cilostazol The risk or severity of bleeding can be increased when Cilostazol is combined with Defibrotide.
Clopidogrel Clopidogrel The risk or severity of bleeding can be increased when Clopidogrel is combined with Defibrotide.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The risk or severity of bleeding can be increased when Erythromycin is combined with Defibrotide.
Estrogen and Progestin (Oral Contraceptives) Estrogen and Progestin (Oral Contraceptives) Conjugated estrogens may decrease the anticoagulant activities of Defibrotide.
Olsalazine Olsalazine The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Defibrotide.
Tacrolimus Tacrolimus The risk or severity of bleeding can be increased when Defibrotide is combined with Tacrolimus.
Triamcinolone Triamcinolone The therapeutic efficacy of Defibrotide can be decreased when used in combination with Triamcinolone.
Doxycycline Injection Doxycycline Injection The risk or severity of bleeding can be increased when Doxycycline is combined with Defibrotide.
Interferon Beta-1b Injection Interferon Beta-1b Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Interferon beta-1b.
Interferon Gamma-1b Injection Interferon Gamma-1b Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Interferon gamma-1b.
Zidovudine Injection Zidovudine Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Zidovudine.
Altretamine Altretamine The risk or severity of bleeding and hemorrhage can be increased when Amphetamine is combined with Defibrotide.
Cefuroxime Cefuroxime The therapeutic efficacy of Defibrotide can be decreased when used in combination with Cefuroxime.
Enoxaparin Injection Enoxaparin Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Enoxaparin.
Meloxicam Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Defibrotide.
Temozolomide Temozolomide The risk or severity of bleeding can be increased when Defibrotide is combined with Temozolomide.
Linezolid Linezolid The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Defibrotide.
Pentosan Polysulfate Pentosan Polysulfate The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Defibrotide.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Defibrotide.
Sirolimus Sirolimus The risk or severity of bleeding can be increased when Defibrotide is combined with Sirolimus.
Epirubicin Epirubicin The risk or severity of bleeding can be increased when Defibrotide is combined with Epirubicin.
Escitalopram Escitalopram The risk or severity of bleeding can be increased when Escitalopram is combined with Defibrotide.
Progesterone Progesterone Progesterone may decrease the anticoagulant activities of Defibrotide.
Duloxetine Duloxetine The risk or severity of hemorrhage can be increased when Duloxetine is combined with Defibrotide.
Norethindrone Norethindrone Norethisterone may decrease the anticoagulant activities of Defibrotide.
Cefditoren Cefditoren The therapeutic efficacy of Defibrotide can be decreased when used in combination with Cefdinir.
Dextroamphetamine Dextroamphetamine The risk or severity of bleeding and hemorrhage can be increased when Amphetamine is combined with Defibrotide.
Peginterferon Alfa-2a Injection Peginterferon Alfa-2a Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Peginterferon alfa-2a.
Peginterferon Alfa-2b (PEG-Intron) Peginterferon Alfa-2b (PEG-Intron) The risk or severity of bleeding can be increased when Defibrotide is combined with Peginterferon alfa-2b.
Isocarboxazid Isocarboxazid The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Defibrotide.
Deferasirox Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Defibrotide is combined with Deferasirox.
Tipranavir Tipranavir Tipranavir may increase the antiplatelet activities of Defibrotide.
Rasagiline Rasagiline The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Defibrotide.
Imatinib Imatinib The risk or severity of bleeding can be increased when Defibrotide is combined with Imatinib.
Bortezomib Bortezomib The risk or severity of bleeding can be increased when Defibrotide is combined with Bortezomib.
Clofarabine Injection Clofarabine Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Clofarabine.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Oxaliplatin.
Rituximab Injection Rituximab Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Rituximab.
Bismuth Subsalicylate Bismuth Subsalicylate The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Defibrotide.
Pemetrexed Injection Pemetrexed Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Pemetrexed.
Vorinostat Vorinostat The risk or severity of bleeding can be increased when Defibrotide is combined with Vorinostat.
Sorafenib Sorafenib The risk or severity of bleeding can be increased when Defibrotide is combined with Sorafenib.
Dasatinib Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Defibrotide.
Omega-3 Fatty Acids Omega-3 Fatty Acids Omega-3 fatty acids may increase the antiplatelet activities of Defibrotide.
Azacitidine Injection Azacitidine Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Azacitidine.
Temsirolimus Temsirolimus The risk or severity of bleeding can be increased when Defibrotide is combined with Temsirolimus.
Nelarabine Injection Nelarabine Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Nelarabine.
Lenalidomide Lenalidomide The risk or severity of bleeding can be increased when Defibrotide is combined with Lenalidomide.
Nilotinib Nilotinib The risk or severity of bleeding can be increased when Defibrotide is combined with Nilotinib.
Toremifene Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Defibrotide.
Bexarotene Bexarotene The risk or severity of bleeding can be increased when Defibrotide is combined with Bexarotene.
Chloramphenicol Injection Chloramphenicol Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Chloramphenicol.
Decitabine Injection Decitabine Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Decitabine.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Arsenic trioxide.
Mitoxantrone Injection Mitoxantrone Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Mitoxantrone.
Desvenlafaxine Desvenlafaxine The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Defibrotide.
Bendamustine Injection Bendamustine Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Bendamustine.
Ixabepilone Injection Ixabepilone Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Ixabepilone.
Irinotecan Injection Irinotecan Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Irinotecan.
Alemtuzumab Injection (Chronic Lymphocytic Leukemia) Alemtuzumab Injection (Chronic Lymphocytic Leukemia) The risk or severity of bleeding can be increased when Defibrotide is combined with Alemtuzumab.
Dexrazoxane Injection Dexrazoxane Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Dexrazoxane.
Ibritumomab Injection Ibritumomab Injection The risk or severity of adverse effects can be increased when Defibrotide is combined with Ibritumomab tiuxetan.
Milnacipran Milnacipran The risk or severity of hemorrhage can be increased when Milnacipran is combined with Defibrotide.
Prasugrel Prasugrel The risk or severity of bleeding can be increased when Defibrotide is combined with Prasugrel.
Everolimus Everolimus The risk or severity of bleeding can be increased when Defibrotide is combined with Everolimus.
Topotecan Topotecan The risk or severity of bleeding can be increased when Defibrotide is combined with Topotecan.
Ulipristal Ulipristal The therapeutic efficacy of Defibrotide can be decreased when used in combination with Ulipristal.
Levonorgestrel Levonorgestrel Levonorgestrel may decrease the anticoagulant activities of Defibrotide.
Dabigatran Dabigatran The risk or severity of bleeding can be increased when Defibrotide is combined with Dabigatran.
Eribulin Injection Eribulin Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Eribulin.
Cabazitaxel Injection Cabazitaxel Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Cabazitaxel.
Ceftaroline Injection Ceftaroline Injection The therapeutic efficacy of Defibrotide can be decreased when used in combination with Ceftaroline fosamil.
Denileukin Diftitox Injection Denileukin Diftitox Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Aldesleukin.
Busulfan Injection Busulfan Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Busulfan.
Potassium Iodide Potassium Iodide Potassium Iodide may increase the anticoagulant activities of Defibrotide.
Cyclophosphamide Injection Cyclophosphamide Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Cyclophosphamide.
Rivaroxaban Rivaroxaban Defibrotide may increase the anticoagulant activities of Rivaroxaban.
Ticagrelor Ticagrelor The risk or severity of bleeding can be increased when Defibrotide is combined with Ticagrelor.
Ruxolitinib Ruxolitinib The risk or severity of bleeding can be increased when Defibrotide is combined with Ruxolitinib.
Melphalan Injection Melphalan Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Melphalan.
Fondaparinux Injection Fondaparinux Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Fondaparinux.
Collagenase Clostridium Histolyticum Injection Collagenase Clostridium Histolyticum Injection The risk or severity of adverse effects can be increased when Defibrotide is combined with Collagenase clostridium histolyticum.
Carfilzomib Injection Carfilzomib Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Carfilzomib.
Iloprost Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Defibrotide.
Bosutinib Bosutinib The risk or severity of bleeding can be increased when Defibrotide is combined with Bosutinib.
Icosapent Ethyl Icosapent Ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Defibrotide.
Tofacitinib Tofacitinib The risk or severity of bleeding can be increased when Defibrotide is combined with Tofacitinib.
Ponatinib Ponatinib The risk or severity of bleeding can be increased when Defibrotide is combined with Ponatinib.
Pomalidomide Pomalidomide The risk or severity of bleeding can be increased when Defibrotide is combined with Pomalidomide.
Ado-trastuzumab Emtansine Injection Ado-trastuzumab Emtansine Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Trastuzumab emtansine.
Apixaban Apixaban Apixaban may increase the anticoagulant activities of Defibrotide.
Levomilnacipran Levomilnacipran The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Defibrotide.
Ibrutinib Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Defibrotide.
Ketorolac Injection Ketorolac Injection The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Defibrotide.
Obinutuzumab Injection Obinutuzumab Injection The risk or severity of adverse effects can be increased when Defibrotide is combined with Obinutuzumab.
Belinostat Injection Belinostat Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Belinostat.
Testosterone Injection Testosterone Injection Testosterone may increase the anticoagulant activities of Defibrotide.
Vorapaxar Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Defibrotide.
Edoxaban Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Defibrotide.
Peginterferon Beta-1a Injection Peginterferon Beta-1a Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Peginterferon beta-1a.
Olaparib Olaparib The risk or severity of bleeding can be increased when Defibrotide is combined with Olaparib.
Blinatumomab Injection Blinatumomab Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Blinatumomab.
Nintedanib Nintedanib The risk or severity of bleeding can be increased when Defibrotide is combined with Nintedanib.
Palbociclib Palbociclib The risk or severity of bleeding can be increased when Defibrotide is combined with Palbociclib.
Dinutuximab Injection Dinutuximab Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Dinutuximab.
Deoxycholic Acid Injection Deoxycholic Acid Injection The risk or severity of adverse effects can be increased when Defibrotide is combined with Deoxycholic acid.
Trabectedin Injection Trabectedin Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Trabectedin.
Obeticholic Acid Obeticholic Acid The risk or severity of adverse effects can be increased when Defibrotide is combined with Obeticholic acid.
Safinamide Safinamide The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Defibrotide.
Betrixaban Betrixaban The risk or severity of bleeding can be increased when Defibrotide is combined with Betrixaban.
Gemtuzumab Ozogamicin Injection Gemtuzumab Ozogamicin Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Gemtuzumab ozogamicin.
Penicillamine Penicillamine The risk or severity of bleeding can be increased when Defibrotide is combined with Penicillamine.
Paclitaxel (with albumin) Injection Paclitaxel (with albumin) Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Paclitaxel.
Caplacizumab-yhdp Injection Caplacizumab-yhdp Injection The risk or severity of bleeding can be increased when Caplacizumab is combined with Defibrotide.
Cladribine Cladribine The risk or severity of bleeding can be increased when Defibrotide is combined with Cladribine.
Calcium Acetate Calcium Acetate The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Defibrotide.
Progestin-Only (drospirenone) Oral Contraceptives Progestin-Only (drospirenone) Oral Contraceptives Drospirenone may decrease the anticoagulant activities of Defibrotide.
Vitamin E (Alpha-Tocopherol) Vitamin E (Alpha-Tocopherol) Vitamin E may increase the antiplatelet activities of Defibrotide.
Fenoprofen Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Defibrotide.
Indomethacin Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Defibrotide.
Mefenamic Acid Mefenamic Acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Defibrotide.
Naproxen Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Defibrotide.
Tolmetin Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Defibrotide.
Sulindac Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Defibrotide.
Trazodone Trazodone The risk or severity of bleeding can be increased when Trazodone is combined with Defibrotide.
Hydroxyurea Hydroxyurea The risk or severity of bleeding can be increased when Defibrotide is combined with Hydroxyurea.
Floxuridine Floxuridine The risk or severity of bleeding can be increased when Defibrotide is combined with Floxuridine.
Methotrexate Injection Methotrexate Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Methotrexate.
Carmustine Carmustine The risk or severity of bleeding can be increased when Defibrotide is combined with Carmustine.
Tranylcypromine Tranylcypromine The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Defibrotide.
Phenelzine Phenelzine The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Defibrotide.
Procarbazine Procarbazine The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Defibrotide.
Thioguanine Thioguanine The risk or severity of bleeding can be increased when Defibrotide is combined with Tioguanine.
Ibuprofen Ibuprofen The risk or severity of bleeding can be increased when Ibuprofen is combined with Defibrotide.
Sulfasalazine Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Defibrotide.
Lomustine Lomustine The risk or severity of bleeding can be increased when Defibrotide is combined with Lomustine.
Doxorubicin Doxorubicin The risk or severity of bleeding can be increased when Defibrotide is combined with Doxorubicin.
Cytarabine Cytarabine The risk or severity of bleeding can be increased when Defibrotide is combined with Cytarabine.
Mechlorethamine Mechlorethamine The risk or severity of bleeding can be increased when Defibrotide is combined with Mechlorethamine.
Dactinomycin Dactinomycin The risk or severity of bleeding can be increased when Defibrotide is combined with Dactinomycin.
Carbamazepine Carbamazepine The risk or severity of bleeding can be increased when Defibrotide is combined with Carbamazepine.
Warfarin Warfarin The risk or severity of bleeding can be increased when Defibrotide is combined with Warfarin.
Meclofenamate Meclofenamate The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Defibrotide.
Daunorubicin Daunorubicin The risk or severity of bleeding can be increased when Defibrotide is combined with Daunorubicin.
Quinine Quinine The therapeutic efficacy of Defibrotide can be increased when used in combination with Quinine.
Sulfinpyrazone Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Defibrotide.
Chlorothiazide Chlorothiazide The therapeutic efficacy of Defibrotide can be decreased when used in combination with Chlorothiazide.
Isosorbide Isosorbide The therapeutic efficacy of Defibrotide can be decreased when used in combination with Isosorbide.
Quinidine Quinidine The therapeutic efficacy of Defibrotide can be increased when used in combination with Quinidine.
Tamoxifen Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Defibrotide.
Mitomycin Mitomycin The risk or severity of bleeding can be increased when Defibrotide is combined with Mitomycin.
Methimazole Methimazole Methimazole may increase the anticoagulant activities of Defibrotide.
Propylthiouracil Propylthiouracil Propylthiouracil may increase the anticoagulant activities of Defibrotide.
Methyclothiazide Methyclothiazide The therapeutic efficacy of Defibrotide can be decreased when used in combination with Methyclothiazide.
Hydrochlorothiazide Hydrochlorothiazide The therapeutic efficacy of Defibrotide can be decreased when used in combination with Hydrochlorothiazide.
Mercaptopurine Mercaptopurine The risk or severity of bleeding can be increased when Defibrotide is combined with Mercaptopurine.
Fluorouracil Injection Fluorouracil Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Fluorouracil.
Cefaclor Cefaclor The therapeutic efficacy of Defibrotide can be decreased when used in combination with Cefaclor.
Cefadroxil Cefadroxil The therapeutic efficacy of Defibrotide can be decreased when used in combination with Cefadroxil.
Cefazolin Injection Cefazolin Injection The therapeutic efficacy of Defibrotide can be decreased when used in combination with Cefazolin.
Cephalexin Cephalexin The therapeutic efficacy of Defibrotide can be decreased when used in combination with Cephalexin.
Cefoxitin Injection Cefoxitin Injection The therapeutic efficacy of Defibrotide can be decreased when used in combination with Cefoxitin.
Dacarbazine Dacarbazine The risk or severity of bleeding can be increased when Defibrotide is combined with Dacarbazine.
Cefotaxime Injection Cefotaxime Injection The therapeutic efficacy of Defibrotide can be decreased when used in combination with Cefotaxime.
Thiotepa Injection Thiotepa Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Thiotepa.
Dipyridamole Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Defibrotide.
Vinblastine Vinblastine The risk or severity of bleeding can be increased when Defibrotide is combined with Vinblastine.
Aspirin Aspirin Acetylsalicylic acid may increase the antiplatelet activities of Defibrotide.
Salsalate Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Defibrotide.
Chlorambucil Chlorambucil The risk or severity of bleeding can be increased when Defibrotide is combined with Chlorambucil.
Cisplatin Injection Cisplatin Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Cisplatin.
Diflunisal Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Defibrotide.
Piroxicam Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Defibrotide.
Streptozocin Streptozocin The risk or severity of bleeding can be increased when Defibrotide is combined with Streptozocin.
Etoposide Etoposide The risk or severity of bleeding can be increased when Defibrotide is combined with Etoposide.
Pentoxifylline Pentoxifylline The therapeutic efficacy of Defibrotide can be increased when used in combination with Pentoxifylline.
Ceftriaxone Injection Ceftriaxone Injection The therapeutic efficacy of Defibrotide can be decreased when used in combination with Ceftriaxone.
Ceftazidime Injection Ceftazidime Injection The therapeutic efficacy of Defibrotide can be decreased when used in combination with Ceftazidime.
Ketoprofen Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Defibrotide.
Cefotetan Injection Cefotetan Injection The therapeutic efficacy of Defibrotide can be decreased when used in combination with Cefotetan.
Flurbiprofen Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Defibrotide.
Mesalamine Mesalamine The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Defibrotide.
Diclofenac Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Defibrotide.
Fluoxetine Fluoxetine The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Defibrotide.
Interferon Alfa-2b Injection Interferon Alfa-2b Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Interferon alfa-2b.
Cefixime Cefixime The therapeutic efficacy of Defibrotide can be decreased when used in combination with Cefixime.
Idarubicin Idarubicin The risk or severity of bleeding can be increased when Defibrotide is combined with Idarubicin.
Fludarabine Injection Fludarabine Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Fludarabine.
Pentostatin Injection Pentostatin Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Pentostatin.
Etodolac Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Defibrotide.
Nabumetone Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Defibrotide.
Teniposide Injection Teniposide Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Teniposide.
Oxaprozin Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Defibrotide.
Venlafaxine Venlafaxine Venlafaxine may increase the antiplatelet activities of Defibrotide.
Fluvoxamine Fluvoxamine The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Defibrotide.
Nefazodone Nefazodone The risk or severity of hemorrhage can be increased when Nefazodone is combined with Defibrotide.
Vinorelbine Injection Vinorelbine Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Vinorelbine.
Carboplatin Injection Carboplatin Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Carboplatin.
Ifosfamide Injection Ifosfamide Injection The risk or severity of bleeding can be increased when Ifosfamide is combined with Defibrotide.
Ticlopidine Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Defibrotide.
Dalteparin Injection Dalteparin Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Dalteparin.
Gemcitabine Injection Gemcitabine Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Gemcitabine.
Docetaxel Injection Docetaxel Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Docetaxel.
Azithromycin Azithromycin The risk or severity of adverse effects can be increased when Azithromycin is combined with Defibrotide.
Selegiline Selegiline The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Defibrotide.
Sertraline Sertraline The risk or severity of bleeding can be increased when Sertraline is combined with Defibrotide.
Cefepime Injection Cefepime Injection The therapeutic efficacy of Defibrotide can be decreased when used in combination with Cefepime.
Cefprozil Cefprozil The therapeutic efficacy of Defibrotide can be decreased when used in combination with Cefprozil.
Cefpodoxime Cefpodoxime The therapeutic efficacy of Defibrotide can be decreased when used in combination with Cefpodoxime.
Paroxetine Paroxetine The risk or severity of hemorrhage can be increased when Paroxetine is combined with Defibrotide.
Citalopram Citalopram The risk or severity of hemorrhage can be increased when Citalopram is combined with Defibrotide.
Capecitabine Capecitabine The risk or severity of bleeding can be increased when Defibrotide is combined with Capecitabine.
Sildenafil Sildenafil The risk or severity of hemorrhage can be increased when Defibrotide is combined with Sildenafil.
Celecoxib Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Defibrotide.
Thalidomide Thalidomide The risk or severity of bleeding can be increased when Defibrotide is combined with Thalidomide.
Balsalazide Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Defibrotide.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists

Still Confused? Ask the pharmacist a question here!